This suggests that hs-cTnT may be useful to risk-stratify patients with acute ischemic stroke or TIA and may also help enhance efficiency of future clinical trials by helping enrich trials with patients with higher CVD event rates.42 Here, TNNT2 is linked to transient ischemic attack.